MD, MPH FRCPC
Preferred method of communication
Research and teaching
- Outcomes and Genomics of Urologic Malignancies including Renal Cell Carcinoma
Summary of Research
Dr. Daniel Heng leads the International mRCC Database Consortium (IMDC) which comprises of over 9,200 patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapies from over 38 cancer centers worldwide. There are associated tissue specimens from corresponding patients in the IMDC biorepository. With this, we have been fortunate to inform clinical practice in terms of prognostic factors, clinical trial benchmarks, sequencing of therapy and cytoreductive nephrectomy in patients with mRCC. This has led to the creation of the IMDC prognostic criteria (a.k.a. Heng Criteria) which are used to prognosticate patients today and guide treatment selection between immune-oncology agents and tyrosine kinase inhibitors.
Dr. Heng is the Division Head of Medical Oncology at the Tom Baker Cancer Center in Calgary, Alberta and a Clinical Professor of Medicine at the University of Calgary. He received his MD from the University of Calgary and trained at the BC Cancer Agency and Cleveland Clinic Taussig Cancer Institute. He has a Masters of Public Health from Harvard University and has a keen interest in outcomes, prognostic factors and clinical trials research in kidney, bladder, prostate and testicular cancers.